Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

No Benefit in Outcomes With Higher Resource Use in Metastatic Prostate Cancer

Increases in monitoring of prostate-specific antigen (PSA) levels and bone health were not associated with improved survival or quality of... Read More

‘Screening Smarter’ for Prostate Cancer

Screening for prostate cancer with the prostate-specific antigen (PSA) test, once widely promoted for all men 50 years and older,... Read More

Immunotherapy for Prostate Cancer: Where Do We Go From Here?

Immunotherapies have emerged as a revolutionary modality for cancer treatment, and a variety of immune-based approaches are currently being investigated... Read More

Early ADT for Incurable Prostate Cancer Has Limited Impact on QOL

Immediate treatment with androgen-deprivation therapy (ADT) for men with asymptomatic non-curable prostate cancer did not have major effects on quality... Read More

Prostate Cancer Patients Can Improve Bone Health With Osteoporosis Medications

Men with non-metastatic prostate cancer who receive androgen deprivation therapy (ADT) risk loss of bone mineral density (BMD) and fractures,... Read More

New ASCO Guideline on Second-Line Hormone Therapy in Prostate Cancer

The American Society of Clinical Oncology (ASCO) issued the first guidance, a provisional clinical opinion (PCO), on second-line hormonal therapy... Read More

Current Guidelines Miss Relevant Germline Mutations in Prostate Cancer

National Comprehensive Cancer Network (NCCN) genetic testing guidelines and Gleason scores do not predict which patients with prostate cancer will... Read More

Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition

Maha H. Hussain, MD, of the Lurie Cancer Center in Chicago, discusses clinical and genomics data from the NCI 9012... Read More

‘High-Intensity’ Sequencing Detected Breast, Prostate Cancers in Blood

A novel high-intensity sequencing approach enabled broad detection of genomic variants in plasma with high rates of concordance with corresponding... Read More

Reducing ADT to 18 Months May Be Sufficient in High-Risk Prostate Cancer

Androgen deprivation therapy (ADT) can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to... Read More

1 2 3 4